Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The deal is pretty straight forward & I don't think Emerald would structure it so if they didn't have most of the terms they plan to execute on significantly researched. NMUS is a great fit in their strategy and longer term plan. Those of us that have been here a while know that NMUS is very slow and light on releasing info. Everyone on the NMUS side is incented to do this deal.
Agreed. The Ole Miss IP alone is worth more than this measly $6m market cap. $50m to $75m market cap for when they announce trials takes this to $1.50 - $2.25.
As long as they fund the $400k balance, move forward with the PIPE in Feb and announce some drug progress/new timelines, nothing to worry about.
The remaining $400,000 of the $900,000 bridge loan is due to fund today if they met all the conditions to fund.
For those of us buying here, we definitely need an organical movement in the share price to uplist to NASDAQ/NYSE. We can only hope that the "recapitalization statement & uplist" in the PR doesn't mean they plan on doing a reverse split just to uplist. With all the under the radar value already in this that should push the share price higher + value Emerald now brings, I hope they wait on any reverse splitting agenda. A 20:1 reverse split to uplist at these prices would be disasterous.
They've been waiting for funding to apply and start trials for NB1111 (glaucoma) and NB1222 (CINV)...if Emerald can supply the funds, everything else is set up to get started. The glaucoma market for their NB1111 is $8B. Those are the announcements we need. No fluff, just funds to start the trials and get those trials going....then we move up. Tee'd up...
NMUS has built significant value + IP over the years. Been under the radar and needed a kick in the pants with industry experience to take it to the next level. Rare oppty where a great company lacks the savvy to increase value. Emerald may be that kick. Looking forward to the next run up...and beyond. Could be huge
A tragedy to see this happen, seems like they can't get in bed with the right people, ever. An all time low. Car dealer? That car dealer is at least bringing in a source of funds. NMUS had $100k in the bank in August means $0 now and no funding plan....doors closing at least for now. Another great potential company that never was
https://finance.yahoo.com/news/nemus-bioscience-announces-presentation-cbd-123000241.html
NEMUS Bioscience, Inc. announced that data recently obtained from the company's research and development partner, the University of Mississippi , will be presented at the American Association of Pharmaceutical ...
Man...i wish they would at least do a simple spell check on their PR.
New FDA orphan drug timing program. Good for biotech if the FDA can follow their new requirements.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm565148.htm
All shareholders have feared a reverse split, however now that they have 20m in funding, they should be able to execute on some of the other milestones to increase value, specifically the 505(b)2 regulatory pathway. IF they can get some of those going, we should see some jumps in the share price. I still expect a reverse split of some sort, but a 5:1 will be significantly better than a 15:1. In my opinion doing a reverse split now vs waiting another 6 months AFTER some of the milestones are hit is immaterial especially since they have funding. I expect management agrees. NYSE is chomping to get them as a customer as they want a cannabinoid biotech as a customer since most see to be going on NASDAQ.
https://finance.yahoo.com/news/nemus-bioscience-reports-prodrug-tetrahydrocannabinol-123000254.html
NEMUS Bioscience, Inc. announced that patents have been granted in Canada and Hong Kong covering the company's proprietary prodrug of THC, THC-valine-hemisuccinate , as well as other amide-ester forms ...
Good article. Summary of what most of us already know; now it's summarized with $20m behind it and out there to help educate others on the sideline or in the dark. Next PR should be more substantial regarding clinical data...they were tee'd up waiting for funding, so as soon as the transaction closes and they can execute some of the logistics, we should see some action.
http://finance.yahoo.com/news/nemus-bioscience-reports-prodrug-tetrahydrocannabinol-123000848.html
NEMUS Bioscience, Inc. announced that an additional United States patent has been granted covering the company's proprietary prodrug of THC, THC-valine-hemisuccinate , as well as other amide-ester forms ...
Now it's all about pipeline execution and uplisting. There is a lot more required to get to a major board than just wanting to be there and this size of a raise allows them to execute short term and move up when the time is right. When they start executing on their catalysts over the next 6 months, the stock price will rise and the uplist will be at a lower reverse split if any at all. Hopefully none is required. Big money still won't touch the pinkies, so getting to a big board is a goal, but need to execute now that they have funding first. Agree that NMUS has a game plan and it's mapped out. It's strategic and how a good early stage biotech becomes successful
Looks like one of our fellow Cannabis buddies has a bit of good news. Huge raise. Further Validation...
http://finance.yahoo.com/news/nemus-bioscience-announces-20-million-123000700.html
NEMUS Bioscience, Inc. today announced the signing of a private placement with an affiliate of Schneider Brothers Ltd, a global closed investment fund with over USD$500 million in assets ...
Yes...20 million things going on.
http://finance.yahoo.com/news/nemus-bioscience-announces-20-million-123000700.html
NEMUS Bioscience, Inc. today announced the signing of a private placement with an affiliate of Schneider Brothers Ltd, a global closed investment fund with over USD$500 million in assets ...
All good points. Its clear the price point of the raise will not catapult the stock since any large investor throwing money at this will be negotiating the best price and have the leverage - I expect it to be around current levels. Right now, its all about the strategic investor and funding the dollar amount in a range that will allow the company to continue on it's next set of events. Alternatively or in addition, any partnership + biz dev deal will secure value and effect the capitalization. NMUS is working all of that now. The company has a history of tight-lipped-ness and no comms from them for the last month proves they are heads down working on these options. The next news announced by NMUS will be next level news and give better visibility to our long term hold and in turn a window into how us longs will increase the value of our holdings. Very exciting. It's time.
It is very misleading to state that VDRM will have to issue more shares to cover legal expenses. 100% unsubstantiated speculation. Will never haopen. A frivolous lawsuit filed by K against 11 defendants INCLUDING Phillips won't require any exhorbant expenses by Dr. O. What a joke.
March 23rd?! Ha...that gave me a good laugh as well.
Every early stage company discloses the "going concern" statement. Go read any report for early stage or growth companies. It is actually an Accounting Principal and boilerplate for a lot of small companies.
Agreed. The silence is telling here. If they were releasing PR, it would prove that they aren't raising money/formulating partnerships. This is the time frame they recently communicated that they would be raising money and with all the recent progress, one could speculate that a B.D. relationship is also in the works. I have no data on that happening, just based on past comms from the Company + silence + knowledge that raising money is critical to move forward at this stage. NMUS is by the book. Non-communication is good news. Other cannabinoid stocks pump, NMUS operating strategically for the long haul and to increase shareholder value. A week or two of no PR is nothing compared to the long term upside.
Kasten completes merger with Dakota announced March 7th - Keough joins = FACT
KAST stock price close on 3/6/2017 $1.40 = FACT
KAST stock price today is $0.51 = FACT
Facts show correlation.
You've obviously never been invested in or a part of an early stage company. If VDRM was spending unnecessary funds frivolously on high dollar SoCal rent, they would be destroyed. How many successful early stage companies bootstrapped and conserved costs -especially on office space until absolutely necessary. Spend money where it needs to be spent....as they're doing. The office situation is a significant positive IMO.
FDA "approval" for a biopharma to sell prescription drugs take years and millions + clinical trials.
FDA registered is for an OTC product and is much easier...hence the 8 weeks. Not sure if they can pull it off in 8 weeks, but "registered" is different than approved prescription drug.
Apple has a secret team working on the holy grail for treating diabetes - pretty cool for those of us interested in working to help diabetes sufferers.
http://cnbc.com/id/104401195
MRSA Indication:
http://newswise.com/articles/new-mrsa-defense-new-study-reports-cannabinoid-effective-against-antibiotic-resistant-mrsa
NMUS operates like a seasoned biotech. They publish news that is relevant and when it is valuable to disclose milestones to the biotech and investment community. This MRSA solution is worth more than the combination of 90% of the companies that are part of that ETF.
No fluff, never has been and never will be with NMUS. Their management team is all biotech guys. They don't mess around with B.S. fluff PR's...just real info - a real biotech that operates that way. When they close on this next round of funding I expect they will announce the funds will be used to start the human trials. When that happens, there will be no looking back.
The push in the industrial / construction market begins...
https://www.google.com/amp/s/www.thestreet.com/amp/story/14059968/1/ekso-bionics-to-present-at-the-groundbreak-2017-construction-conference.html
I'm in Houston this week and hope to have time to get by the conference tomorrow to understand more about the company. Email exchange w/ Doc below.
----- Forwarded Message -----
From: "info@viadermalicensing.com" <info@viadermalicensing.com>
To: frozenspokes
Sent: Wednesday, March 22, 2017 4:38 PM
Subject: Re: DFCON
Hi 'frozenspokes',
I will be at the Poster Presentation on Friday between 11.40 and 2pm
Dr. Chris Ayo Otiko,
President & CEO
ViaDerma, Inc
Corporate Headquarters
4640 Admiralty Way Suite 500, Marina Del Rey, CA 90292
Phone: (310) 496-5744
Fax: (310) 943-1457
http://viadermalicensing.com/
On Wed, 22 Mar, 2017 at 12:23 PM, frozenspokes wrote:
To: sales@viadermalicensing.com
Cc: info@viadermalicensing.com
Hi Guys,
I'm planning on attending the conference in Houston this week. I know Dr. Otiko will be presenting an abstract & hope to have a conversation with him. Will Ken or Ivan be in attendance? It would be nice to connect with the team to discuss the company and the products.
Thanks in advance.
MRSA Synergy = NEMUS is crushing it under the radar and continues to expand its pipeline & become the go to company for areas where they focus and excel.
http://www.nemusbioscience.com/investor-relations/investor-news/investor-news-details/2017/NEMUS-Bioscience-and-the-University-of-Mississippi-Announce-Significant-Anti-MRSA-Synergy-Data-Utilizing-Proprietary-Cannabinoid-Based-Anti-Infective-Platforms/default.aspx
Nice chart action.
Last week's patent talk got me intrigued, so i dug around this weekend. I can't find any patents for IMLFF. Funny that someone mentioned NMUS last week b/c in my research, I did find Cannabinoid Glaucoma patents for them both in the USA and internationally for their drug. They have other patents also and just released the announcement below this morning (timely). I'm going to dig into Nemus as well - looks like a gem that hasn't been discovered yet & they're starting trials soon. Will check out their board and post more over there if applicable. Hope someone can help on the IMLFF patents in the mean time.
https://finance.yahoo.com/news/nemus-bioscience-signs-development-agreement-123000654.html
NEMUS Bioscience, Inc. ( OTCQB : NMUS ) announced that the company has signed a development agreement with Nanomerics Ltd. of the United Kingdom, to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, which is the active component of Nemus drug candidate NB1111 being developed for the treatment of glaucoma. The aim of the agreement is to conduct initial studies assessing the preparation of clinical-grade eye drops using the patented Molecular Envelope Technology (MET) developed by Nanomerics. Work under the agreement will commence on a future date to be determined by Nemus in connection with its development plans and corporate objectives.
"Nanomerics looks forward to working with Nemus on creating medicines that address the medical need for the improved treatment of glaucoma. Nemus, as the only cannabinoid company we are aware of with a complement of prodrugs and analogues of THC and CBD, is uniquely placed to potentially develop these for use in multiple forms of ocular disease," commented Professor Andreas Schätzlein, co-founder and CEO of Nanomerics. Nanomerics' CSO and co-founder Professor Ijeoma Uchegbu explained, "We feel that the MET platform will help NB1111 deliver in the clinic what has already been shown in several animal studies. Namely, penetration into multiple chambers of the eye, a non-opaque eye drop, and a neutral-pH at delivery to lower the risk of eye irritation which is an adverse event seen with some established therapies in glaucoma."
Another quality article stating facts around the progress and momentum for NMUS. The real deal, quietly building value.
http://ddn-news.com/index.php?newsarticle=11376
Very informative article (Case Study #3) for DD on NMUS. Talk about value whereby NMUS is the real deal w/ their partnerships, government coverage and pipeline:
http://cen.acs.org/articles/95/i11/Building-pharmaceutical-outsourcing-partnerships.html
2nd Report with Ulcer/Sore/MRSA treatments:
http://www.phillipscompany.4t.com/TSTEM.pdf
Dr. O quoted in the report.
{Caution: graphic photos}
TetraStem research report DD
11/26/2016: The Miranda report related to treating her spinal cord injuries via stem cell applications: http://www.phillipscompany.4t.com/Miranda.pdf
Good medical detail in the report + re: Phillips from the report:
Phillips Company operates as a not-for
-profit FDA-registered pharmaceutical manufacturing
company
, with a manufacturing capability of up to 50,000 units per month.
We do not advertise.
The company operates as a product development company
, having developed and licensed 22
products since 2007. Our focus is on the development of world class products which can deliver
performance not available from products anywhere else in the world.
We are self funded and do
not accept investment capital, but we do license, assign and sell our technologies, trade secrets
(intellectual property) and products to other companies.
We provide our products to all buyers at
low, wholesale prices.